Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' GENB.O shares fell 6.25% in its Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market volatility kept investors cautious toward new listings.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.